A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies

Cutaneous T-cell lymphomas (CTCLs) represent a group of rarely occurring and clinically and pathologically heterogeneous diseases that are considered incurable at advanced stages. Current treatments provide limited clinical benefit and are thus largely amenable to improvement. An antibody-based CTCL...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology
Main Authors: Sicard, Hélène, Bonnafous, Cécile, Morel, Ariane, Bagot, Martine, Bensussan, Armand, Marie-Cardine, Anne
Format: Artigo
Language:Inglês
Published: Taylor & Francis 2015
Subjects:
Author's View
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4570095/
https://ncbi.nlm.nih.gov/pubmed/26405593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1022306
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items